| Q54426699 | A new method to synthesize creatine derivatives. |
| Q33844763 | A potential role for creatine in drug abuse? |
| Q31151655 | AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review |
| Q55069818 | Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth. |
| Q43130748 | Ammonia toxicity to the brain: effects on creatine metabolism and transport and protective roles of creatine |
| Q46670732 | Ammonium alters creatine transport and synthesis in a 3D culture of developing brain cells, resulting in secondary cerebral creatine deficiency. |
| Q36597762 | An immortalized human blood-nerve barrier endothelial cell line for in vitro permeability studies |
| Q41215893 | Axonal and glial microstructural information obtained with diffusion-weighted magnetic resonance spectroscopy at 7T. |
| Q27349876 | Beneficial effects of estrogen in a mouse model of cerebrovascular insufficiency |
| Q47930663 | Cell-Type-Specific Spatiotemporal Expression of Creatine Biosynthetic Enzyme S-adenosylmethionine:guanidinoacetate N-methyltransferase in Developing Mouse Brain |
| Q36874299 | Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development |
| Q37976595 | Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers |
| Q30986125 | Creatine deficiency syndromes |
| Q28306965 | Creatine deficiency syndromes and the importance of creatine synthesis in the brain |
| Q24631151 | Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? |
| Q34206841 | Creatine metabolism differs between mammals and rainbow trout (Oncorhynchus mykiss). |
| Q27006952 | Creatine supplementation during pregnancy: summary of experimental studies suggesting a treatment to improve fetal and neonatal morbidity and reduce mortality in high-risk human pregnancy |
| Q24811264 | Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. |
| Q40436889 | Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice |
| Q89986397 | Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts |
| Q30523794 | Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency |
| Q90103177 | Deletion of the Creatine Transporter (Slc6a8) in Dopaminergic Neurons Leads to Hyperactivity in Mice |
| Q48924075 | Detection of a novel intragenic rearrangement in the creatine transporter gene by next generation sequencing |
| Q33477139 | Developmental changes in the expression of creatine synthesizing enzymes and creatine transporter in a precocial rodent, the spiny mouse |
| Q44971585 | Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis |
| Q48306461 | Disturbed energy metabolism and muscular dystrophy caused by pure creatine deficiency are reversible by creatine intake |
| Q50658680 | Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency. |
| Q33729818 | Effects of creatine and β-guanidinopropionic acid and alterations in creatine transporter and creatine kinases expression in acute seizure and chronic epilepsy models |
| Q37817010 | Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult |
| Q34247638 | In vitro study of uptake and synthesis of creatine and its precursors by cerebellar granule cells and astrocytes suggests some hypotheses on the physiopathology of the inherited disorders of creatine metabolism |
| Q39239140 | Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier |
| Q37313443 | Mechanisms of the penetration of blood-borne substances into the brain |
| Q35557433 | New approaches to in vitro models of blood-brain barrier drug transport. |
| Q39768257 | Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency |
| Q46467675 | Risk for metabolic syndrome predisposes to alterations in the thalamic metabolism |
| Q37894600 | SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments |
| Q38922312 | Solute Carriers in the Blood-Brain Barier: Safety in Abundance |
| Q35493114 | Stuck at the bench: Potential natural neuroprotective compounds for concussion |
| Q34437605 | Substituted cysteine accessibility of the third transmembrane domain of the creatine transporter: defining a transport pathway |
| Q28200789 | The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits |
| Q38873820 | The effects of creatine supplementation on striatal neural progenitor cells depend on developmental stage |
| Q33648688 | The molecular and biophysical characterization of the human blood-nerve barrier: current concepts |
| Q34089086 | Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives |
| Q37847248 | Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders |
| Q64120897 | UNICORN Babies: Understanding Circulating and Cerebral Creatine Levels of the Preterm Infant. An Observational Study Protocol |
| Q38208767 | X-linked creatine transporter deficiency: clinical aspects and pathophysiology |
| Q34182787 | γ-Aminobutyric acid transporter 2 mediates the hepatic uptake of guanidinoacetate, the creatine biosynthetic precursor, in rats |